# CD147-CAR T Cells for Relapsed/Refractory T Cell Non-Hodgkin's Lymphoma

> **NCT05013372** · EARLY_PHASE1 · UNKNOWN · sponsor: **Peking University People's Hospital** · enrollment: 12 (estimated)

## Conditions studied

- T-cell Non-Hodgkin's Lymphoma

## Interventions

- **DRUG:** CD147- CAR T cells

## Key facts

- **NCT ID:** NCT05013372
- **Lead sponsor:** Peking University People's Hospital
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-01
- **Primary completion:** 2024-01-01
- **Final completion:** 2025-01-01
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2022-08-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05013372

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05013372, "CD147-CAR T Cells for Relapsed/Refractory T Cell Non-Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05013372. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*